News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Geron Corporation Initiates Clinical Trial of GRN163L in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma
October 20, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) today announced that it has enrolled the first multiple myeloma patient in a clinical trial of its telomerase inhibitor drug, GRN163L, in combination with other treatments.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase I
MORE ON THIS TOPIC
Vaccines
CDC Highlights Efficacy of COVID-19 Shots in Kids Amid FDA Probe of Alleged Deaths
December 12, 2025
·
2 min read
·
Tristan Manalac
Parkinson’s disease
AC Immune’s Parkinson’s Immunotherapy Appears to Slow Disease Progression
December 11, 2025
·
1 min read
·
Annalee Armstrong
Obesity
Lilly’s Retatrutide Scores Triple Trial Triumph With 26% Weight Loss, But New Safety Signal Emerges
December 11, 2025
·
3 min read
·
Annalee Armstrong
Breast cancer
Pfizer Builds Case for Tukysa as ‘New Standard Regimen’ in First-Line Metastatic Breast Cancer
December 11, 2025
·
2 min read
·
Tristan Manalac
